AI Article Synopsis

  • Non-viral gene therapy is a promising option for treating hereditary skin diseases, but research in this field is limited.
  • A new gene delivery system using highly branched poly(β-amino ester)s (HPAEs) has been developed to treat recessive dystrophic epidermolysis bullosa (RDEB) and has shown success in restoring type VII collagen expression in lab tests.
  • The effective use of HPAEs in RDEB treatment suggests that similar polymeric gene delivery vectors could enhance gene therapy for other challenging genetic skin conditions.

Article Abstract

Non-viral gene therapy for hereditary skin diseases is an attractive prospect. However, research efforts dedicated to this area are rare. Taking advantage of the branched structural possibilities of polymeric vectors, we have developed a gene delivery platform for the treatment of an incurable monogenic skin disease - recessive dystrophic epidermolysis bullosa (RDEB) - based on highly branched poly(β-amino ester)s (HPAEs). The screening of HPAEs and optimization of therapeutic gene constructs, together with evaluation of the combined system for gene transfection, were comprehensively reviewed. The successful restoration of type VII collagen (C7) expression both in vitro and in vivo highlights HPAEs as a promising generation of polymeric vectors for RDEB gene therapy into the clinic. Considering that the treatment of patients with genetic cutaneous disorders, such as other subtypes of epidermolysis bullosa, pachyonychia congenita, ichthyosis and Netherton syndrome, remains challenging, the success of HPAEs in RDEB treatment indicates that the development of viable polymeric gene delivery vectors could potentially expedite the translation of gene therapy for these diseases from bench to bedside.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.addr.2021.113842DOI Listing

Publication Analysis

Top Keywords

gene delivery
12
gene therapy
12
highly branched
8
branched polyβ-amino
8
polyβ-amino esters
8
gene
8
hereditary skin
8
skin diseases
8
polymeric vectors
8
epidermolysis bullosa
8

Similar Publications

Doxorubicin, a widely used anthracycline antibiotic, has been a cornerstone in cancer chemotherapy since the 1960s. In addition to doxorubicin, anthracycline chemotherapy medications include daunorubicin, idarubicin, and epirubicin. For many years, doxorubicin has been the chemotherapy drug of choice for treating a broad variety of cancers.

View Article and Find Full Text PDF

AIP56, an AB toxin secreted by subsp. , has tropism for myeloid cells.

Front Immunol

January 2025

Fish Immunology and Vaccinology Group, Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Porto, Portugal.

Introduction: The AB-type toxin AIP56 is a key virulence factor of Photobacterium damselae subsp. piscicida (Phdp), inducing apoptosis in fish immune cells. The discovery of AIP56-like and AIP56-related toxins in diverse organisms, including human-associated Vibrio strains, highlights the evolutionary conservation of this toxin family, suggesting that AIP56 and its homologs may share conserved receptors across species.

View Article and Find Full Text PDF

Background: This study aimed to investigate the effects of ginseng non-edible callus-derived extracellular vesicle (GNEV) on skin regeneration, particularly focusing on its impact on proliferation and migration in human dermal fibroblast (HDF).

Methods: GNEV was isolated from ginseng non-edible callus using sequential filtration and size exclusion chromatography (SEC). The extracellular vesicle was characterized using nanoparticle tracking analysis (NTA).

View Article and Find Full Text PDF

Background: Chitosan nanoparticles (CsNPs) are an effective and inexpensive approach for DNA delivery into live cells. However, most CsNP synthesis protocols are not optimized to allow long-term storage of CsNPs without loss of function. Here, we describe a protocol for CsNP synthesis, lyophilization, and sonication, to store CsNPs and maintain transfection efficiency.

View Article and Find Full Text PDF

Gene therapy has long been a cornerstone in the treatment of rare diseases and genetic disorders, offering targeted solutions to conditions once considered untreatable. As the field advances, its transformative potential is now expanding into oncology, where personalized therapies address the genetic and immune-related complexities of cancer. This review highlights innovative therapeutic strategies, including gene replacement, gene silencing, oncolytic virotherapy, CAR-T cell therapy, and CRISPR-Cas9 gene editing, with a focus on their application in both hematologic malignancies and solid tumors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!